A detailed history of Axq Capital, LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Axq Capital, LP holds 19,680 shares of ACAD stock, worth $319,209. This represents 0.07% of its overall portfolio holdings.

Number of Shares
19,680
Previous 16,779 17.29%
Holding current value
$319,209
Previous $310 Million 3.08%
% of portfolio
0.07%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$14.62 - $18.42 $42,412 - $53,436
2,901 Added 17.29%
19,680 $320 Million
Q1 2024

May 14, 2024

BUY
$17.79 - $30.86 $147,265 - $255,459
8,278 Added 97.38%
16,779 $310 Million
Q4 2023

Feb 13, 2024

SELL
$20.78 - $31.77 $229,619 - $351,058
-11,050 Reduced 56.52%
8,501 $266 Million
Q3 2023

Nov 14, 2023

BUY
$20.84 - $33.47 $407,442 - $654,371
19,551 New
19,551 $407 Million
Q1 2023

May 10, 2023

BUY
$16.32 - $20.92 $201,372 - $258,131
12,339 New
12,339 $232 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.63B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Axq Capital, LP Portfolio

Follow Axq Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axq Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Axq Capital, LP with notifications on news.